Mepolizumab yields lower rate of moderate/severe exacerbations in COPD

by

For patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations and a blood eosinophil count of at least 300 cells/µL, mepolizumab leads to a lower annualized rate of moderate or severe exacerbations, according to a study published in the New England Journal of Medicine.

Leave A Comment

Your email address will not be published. Required fields are marked *